CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

decisions of limitations and stop processingWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug1161 IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care. Wiki 1.00

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.09
D007239 Infection NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Study of the Consequences of Infection on Compliance of Modalities of Decisions of Limitations and Stops of Treatments

This survey is performed to examine if during the Covid's crisis, the practitionner's have respected the modalities of the law about the end of life, in particular concerning limitations and stop of therapeutics

NCT04452487 Patient Hospitalized in Disease Infectious Patient Hospitalized in Disease Infectious Unit Patient Hospitalized in Intensive Reanimation Unit Patient Hopsitalized in Internal Medicine Unit Behavioral: decisions of limitations and stop processing
MeSH:Infection Communicable Diseases

Primary Outcomes

Description: The conformity of the modalities of the decisions of limitations and therapeutic stops will be evaluated by a composite criterion defined by the simultaneous presence of the 3 main modalities imposed by the Clayes-Leonetti law to achieve a limitation that are : An outside consultant's opinion ( required if no advance directives), the caregiver collegial discussion or adherence to patient advance directives, notification of decision in the medical record

Measure: decisions of limitations and therapeutic stops

Time: at the end of patient's hospitalization, an average of one month

Secondary Outcomes

Description: notification of the decision, the conclusions of the discussions, the opinion of the consultant and the arguments given to justify the LAT

Measure: Characteristics of the notification of LAT procedure

Time: at the end of patient's hospitalization, an average of one month

Description: number and status of caregivers who participated to the collegial discussion

Measure: Characteristics of the LAT procedure (persons who participated to the collegial discussion)

Time: at the end of patient's hospitalization, an average of one month

Description: formal elements of the consultant's reasoned opinion ( legal term) in the file

Measure: Characteristics of consultant's reasoned opinion for the LAT procedure

Time: at the end of patient's hospitalization, an average of one month

Description: formal elements of advance directives

Measure: Characteristics of the LAT procedure

Time: at the end of patient's hospitalization, an average of one month

Description: number of beds, number of caregivers (medical, paramedical, internal external), number of admissions during periods of study

Measure: Characteristics of units

Time: day 0

Description: measured in year

Measure: Age of physicians

Time: Day 0

Description: male or female

Measure: gendrer of physicians

Time: Day 0

Description: Measured in year of experience

Measure: Exparience of physicians

Time: Day 0

Description: professional status

Measure: Characteristics of physicians

Time: Day 0

Description: measured in year

Measure: Age of patients

Time: day 0

Description: comorbidities

Measure: patient's history

Time: day 0

Description: COVID19 infection (yes or no)

Measure: COVID-19 patient's status

Time: day 0

Description: hospitalization reason

Measure: Characteristics of hospitalization's patients

Time: day 0

Description: organ failure

Measure: Characteristics of affected organ

Time: day 0

Description: severity score

Measure: Characteristics of patients

Time: day 0

Description: fate

Measure: final patient status

Time: day 0

Description: family presence or relatives

Measure: patient's environnement

Time: day 0

No related HPO nodes (Using clinical trials)